Clinical Trials Logo

Sepsis-Associated Encephalopathy clinical trials

View clinical trials related to Sepsis-Associated Encephalopathy.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06112119 Not yet recruiting - Clinical trials for Sepsis-Associated Encephalopathy

Role of MSCT Volumetry in Assessment of Brain Atrophy in Septic Patients

Start date: November 1, 2023
Phase:
Study type: Observational

assessment of brain atrophy associated with septic ICU patients by using MSCT Volumetry

NCT ID: NCT05451537 Not yet recruiting - Clinical trials for Sepsis-Associated Encephalopathy

Correlation of Formyl Peptide Receptor 1 With Sepsis-related Encephalopathy

Start date: September 1, 2022
Phase:
Study type: Observational

The pathogenesis of sepsis-associated encephalopathy (SAE) is unclear, Formylpeptide receptor 1 (FPR1) is a cell membrane receptor that recruits leukocytes and mediates inflammatory responses after activation, but its role and mechanism in SAE are unknown. This project intends to clarify the relationship between FPR1 activation and SAE from the clinical. The investigators enrolled 100 patients with sepsis in ICU. Patients were divided into two groups according to diagnostic criteria: SAE group and none-SAE group. Whole blood was collected. The serum FPR1 protein level was measured using a commercial enzyme-linked immunosorbent assay. After whole blood RNA was extracted, the expressions of FPR1 and a reference gene were quantified by an automated one-step Taqman RT-PCR assay. Multiple logistical regression analysis was used to identify the independent factors (including FPR1 activation) for the prediction of SAE outcomes.